Case Number 3539
Request Date 19/03/2014
Completion Date 31/03/2014

 

Details of the Request

For your Trust please could you supply the total number of patients treated with biologics for the following conditions, split by the named biologic for two time periods: 1st January - 30th June 2013 and 1st July to 31st December 2013.

 

Conditions:

  • Rheumatoid Arthritis
  • Ankylosing Spondylitis [if split by individual Arthropathy is not possible, please state total for Spondylarthropathies]
  • Psoriatic Arthritis
  • Psoriasis
  • Crohn's disease
  • Ulcerative Colitis

 

Biologics;

  • Abatacept [Orencia]
  • Adalimumab [Humira]
  • Anakinra [Kineret]
  • Certolizumab [Cimzia]
  • Etanercept [Enbrel]
  • Golimumab [Simponi]
  • Infliximab [Remicade]
  • Rituximab [Mabthera]
  • Tocilizumab [Ro Actemra]
  • Ustekinumab [Stelara]
  • Others

 

Details of the Response

Please see the attached completed spreadsheet.

This was collected using our high cost drugs approvals database. Once a patient is approved they remain so until they stop, switch drugs or until the end of the NICE approved course of treatment. Therefore, we have considered the patients treated between 1st Jan and 30th June 2013 to be all patients approved during that time period PLUS all patients approved prior to that period who remained on treatment during that period.

Hence, in the second period of 1st July to 31st December 2013 we have recorded in black text the new approvals for that period PLUS in red text the number of patients continuing from the prior period. The total of the two will be the total number of patients we treated during that time.

The Trust has no appropriate data to complete ‘Other’ – we have no other Biologics recorded as being used for these indications. Please consider ‘Other’ usage to be Zero.